ReviewESMO open2016
The European Cancer Patient's Bill of Rights, update and implementation 2016.
Review in ESMO open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The requirements of a specialist breast centre.Breast (Edinburgh, Scotland) · 2020Guideline
- Common sense oncology values to action: a patient-led framework for randomized clinical trial design.Journal of the National Cancer Institute · 2026Article
- Cancer inequalities in the United Kingdom and the data used to measure them: a scoping review.The Lancet regional health. Europe · 2025Review
- European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies.HemaSphere · 2025Article
- Disease burden of trachea, bronchus and lung cancer 1990-2021 and global trends projected to 2035.Scientific reports · 2025Article
- Physical Therapists in Oncology Settings: Experiences in Delivering Cancer Rehabilitation Services, Barriers to Care, and Service Development Needs.Physical therapy · 2022Article
- Breast cancer patient perspective on opportunities and challenges of a genetic test aimed to predict radio-induced side effects before treatment: Analysis of the Italian branch of the REQUITE project.La Radiologia medica · 2021Article
- Challenges and solutions to embed cancer survivorship research and innovation within the EU Cancer Mission.Molecular oncology · 2021Article
- Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe.Breast (Edinburgh, Scotland) · 2021Review
- The Oncology Data Network (ODN): Methodology, Challenges, and Achievements.The oncologist · 2020Article
- Empowering patients in decision-making in radiation oncology - can we do better?Molecular oncology · 2020Review
- Analysis of Global Pediatric Cancer Research and Publications.JCO global oncology · 2020Article
- Comparison of the importance and observance of the patient's bill of rights from the perspectives of patients and personnel of hospitals in Kerman.Journal of medical ethics and history of medicine · 2020Article
- The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care.The oncologist · 2020Article
- Management of patients with metastatic prostate cancer (mPC) in a rural part of North Norway with a scattered population: does living near the department of oncology translate into a different pattern of care and survival?International journal of circumpolar health · 2019Article
- The European Cancer Patient Coalition and its central role in connecting stakeholders to advance patient-centric solutions in the mission on cancer.Molecular oncology · 2019Review
- How I treat cancer special issue.ESMO open · 2019Article
- Taking patient reported outcomes centre stage in cancer research - why has it taken so long?Research involvement and engagement · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
60 authors.
Funding
Abstract
In this implementation phase of the European Cancer Patient's Bill of Rights (BoR), we confirm the following three patient-centred principles that underpin this initiative:The right of every European citizen to receive the most accurate information and to be proactively involved in his/her care.The right of every European citizen to optimal and timely access to a diagnosis and to appropriate specialised care, underpinned by research and innovation.The right of every European citizen to receive care in health systems that ensure the best possible cancer prevention, the earliest possible diagnosis of their cancer, improved outcomes, patient rehabilitation, best quality of life and affordable health care. The key aspects of working towards implementing the BoR are:Agree our high-level goal. The vision of 70% long-term survival for patients with cancer in 2035, promoting cancer prevention and cancer control and the associated progress in ensuring good patient experience and quality of life.Establish the major mechanisms to underpin its delivery. (1) The systematic and rigorous sharing of best practice between and across European cancer healthcare systems and (2) the active promotion of Research and Innovation focused on improving outcomes; (3) Improving access to new and established cancer care by sharing best practice in the development, approval, procurement and reimbursement of cancer diagnostic tests and treatments.Work with other organisations to bring into being a Europe based centre that will (1) systematically identify, evaluate and validate and disseminate best practice in cancer management for the different countries and regions and (2) promote Research and Innovation and its translation to maximise its impact to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.